Skip to main content

Table 1 Demographic and clinical characteristics of patient in therapeutic efficacy studies to evaluate artemether-lumefantrine or artesunate + sulfadoxine-pyrimethamine in Sudan (2010–2015)

From: High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010–2015): evidence from in vivo and molecular marker studies

Drug

Site

Study years

N

Males

Age group

Temperature D0

Parasite count (/uL), D0

<5 years

5–14 years

≥15 years

N

(%)

N

(%)

N

(%)

N

(%)

Mean

(SD)

Geometric mean

Range

AS + SP

Kosti

2010

92

57

(62)

14

(15)

59

(64)

19

(21)

38.1

(1)

26,202

(5470–90,940)

Sennar

2010

97

51

(53)

5

(5)

69

(71)

23

(24)

38.4

(0.9)

13,973

(1800–71,889)

Gedaref

2011–12

100

53

(53)

17

(17)

52

(52)

31

(31)

39

(1.1)

11,725

(1600–129,167)

Kassala

2011

75

44

(59)

24

(32)

17

(23)

34

(45)

38.1

(0.8)

5917

(1020–68,421)

Kosti

2011

98

55

(56)

17

(17)

63

(64)

18

(18)

38.1

(1.1)

14,249

(3380–88,098)

Sennar

2011

95

43

(44)

9

(10)

71

(75)

15

(16)

37.9

(1.2)

10,592

(1400–57,910)

Kosti

2012–13

95

45

(47)

20

(21)

58

(61)

17

(18)

37.1

(1.1)

18,541

(1120–97,143)

Damazin

2013–14

100

61

(61)

19

(19)

67

(67)

14

(14)

37.7

(1)

15,657

(1460–90,000)

Sennnar

2013–14

88

57

(65)

9

(10)

76

(86)

3

(3)

37.1

(0.9)

8252

(1140–35,500)

New Halfa

2013–14

80

40

(50)

14

(18)

25

(31)

41

(51)

38.6

(1.8)

12,798

(2123–116,666)

Gedaref

2014–15

93

47

(51)

15

(16)

58

(62)

20

(22)

37.6

(0.9)

11,165

(1053–52,319)

AL

Damazin

2010

67

32

(48)

0

(0)

30

(45)

37

(55)

38.2

(0.6)

11,203

(1675–100,000)

Kassala

2010

85

57

(67)

11

(13)

40

(47)

34

(40)

37.8

(1)

11,245

(1500–97,142)

Kosti

2012–13

101

64

(63)

7

(7)

44

(44)

50

(50)

38.2

(0.9)

5339

(1000–45,756)

Damazin

2013

98

54

(55)

11

(11)

64

(65)

23

(24)

38.1

(0.9)

12,095

(3020–70,961)

Kassala

2013–14

84

53

(63)

12

(14)

32

(38)

40

(48)

38

(0.7)

16,226

(1100–90,000)

Sennar

2013–14

42

22

(52)

5

(12)

26

(62)

11

(26)

38.5

(1.2)

18,695

(3280–93,939)

Gedaref

2013–14

35

26

(74)

1

(3)

10

(29)

24

(69)

37.6

(0.9)

8524

(1060–75,000)

Sennar

2014

41

22

(54)

8

(20)

25

(61)

8

(20)

37.8

(1.1)

10,827

(1040-78,110)

Gedaref

2014–15

42

29

(69)

7

(17)

23

(55)

12

(29)

37

(1.1)

4741

(1300–14,240)

  1. SD standard deviation